AIM Operating Income from 2010 to 2024
| AIM Stock | USD 0.23 0.02 9.52% |
Operating Income | First Reported 1995-01-31 | Previous Quarter -3.7 M | Current Value -4.5 M | Quarterly Volatility 1.7 M |
Check AIM ImmunoTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AIM ImmunoTech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 226.1 K, Total Revenue of 386.8 K or Gross Profit of 168 K, as well as many indicators such as Price To Sales Ratio of 101, Dividend Yield of 0.0 or PTB Ratio of 1.98. AIM financial statements analysis is a perfect complement when working with AIM ImmunoTech Valuation or Volatility modules.
AIM | Operating Income |
Latest AIM ImmunoTech's Operating Income Growth Pattern
Below is the plot of the Operating Income of AIM ImmunoTech over the last few years. Operating Income is the amount of profit realized from AIM ImmunoTech operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of AIM ImmunoTech is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. AIM ImmunoTech's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AIM ImmunoTech's overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
AIM Operating Income Regression Statistics
| Arithmetic Mean | (16,923,947) | |
| Coefficient Of Variation | (44.29) | |
| Mean Deviation | 5,218,076 | |
| Median | (16,650,000) | |
| Standard Deviation | 7,495,951 | |
| Sample Variance | 56.2T | |
| Range | 30.9M | |
| R-Value | (0.62) | |
| Mean Square Error | 36.9T | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | (1,046,441) | |
| Total Sum of Squares | 786.6T |
AIM Operating Income History
About AIM ImmunoTech Financial Statements
AIM ImmunoTech investors utilize fundamental indicators, such as Operating Income, to predict how AIM Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | -31.9 M | -30.3 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of AIM ImmunoTech Correlation against competitors. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.48) | Revenue Per Share 0.004 | Quarterly Revenue Growth 0.19 | Return On Assets (0.80) | Return On Equity (1.55) |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.